Hypersensitivity reaction to certolizumab pegol in a patient affected by psoriatic arthritis

Abstract

The pathogenic mechanism of hypersensitivity reactions (HSRs) to monoclonal antibodies is not fully understood. HSRs can occur after the first exposure or multiple exposures and include acute infusion reactions induced by cytokine release, besides Type I, Type III, and Type IV reactions.). We reported a case of anaphylactic reaction to certolizumab pegol in a patient affected by psoriatic arthritis and a possible management of this condition.

Successful Subcutaneous Desensitization to Certolizumab Pegol

“…Adverse effects, including paradoxical psoriasiform eruptions or hypocomplementemic urticaria-vasculitis have been reported [2,3]. Besides, hypersensitivity reactions after CZP administration have been described, both to the anti-TNF portion of the antibody and to the PEG component [4,5].…”